- Home
- BMRN vs JAZZ Comparison
BMRN vs JAZZ Comparison
Compare BMRN & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMRN | JAZZ |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 10.4B |
| IPO Year | 1999 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BMRN | JAZZ |
|---|---|---|
| Price | $59.68 | $180.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | $87.24 | ★ $215.92 |
| AVG Volume (30 Days) | ★ 2.1M | 974.4K |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | $1,313,646,000.00 | ★ $1,618,693,000.00 |
| Revenue This Year | $13.34 | $6.17 |
| Revenue Next Year | $11.42 | $7.66 |
| P/E Ratio | $32.80 | ★ N/A |
| Revenue Growth | ★ 17.62 | N/A |
| 52 Week Low | $50.76 | $95.49 |
| 52 Week High | $73.18 | $198.00 |
Technical Indicators
Market Signals| Indicator | BMRN | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 51.77 |
| Support Level | $56.08 | $159.78 |
| Resistance Level | $60.52 | $182.99 |
| Average True Range (ATR) | 2.28 | 6.27 |
| MACD | -0.28 | -0.51 |
| Stochastic Oscillator | 15.11 | 37.33 |
Price Performance
Historical ComparisonAbout BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.